K36 therapeutics announces multiple poster presentations highlighting the first clinical data for ktx-1001 and other developmental compounds at the 66th american society of hematology (ash) annual meeting

Results collectively support the mechanism of action and rationale for targeting mmset in patients with multiple myeloma cambridge, mass. , dec. 3, 2024 /prnewswire/ -- k36 therapeutics, inc. ("k36"), a clinical-stage biotech company focused on developing its first-in-class mmset / nsd2 inhibitor ktx-1001 for t(4;14) multiple myeloma, today announced upcoming poster presentations outlining data from its ktx-1001 and ktx-1029 programs at the 66th american society of hematology (ash) annual meeting and exposition held december 6-10, 2024 in san diego, california.
ASH Ratings Summary
ASH Quant Ranking